Muscle News and Research

RSS

Probiotic supplements can benefit body during and after antibiotic use

Recent data suggests that the average American is bombarded with up to 5,000 varying media messages on a daily basis, which can make it tricky to discern fact from fiction. When it comes to your health, there should be absolutely no doubt that the products you select are effectively working to produce the desired results. This is especially true when it comes to the use of probiotics with antibiotics, because some forms are less effective when combined with antibiotics.

19 Dec 2012

Arthritis, rheumatism and total joint arthroplasty: an interview with Dr Ravi and Dr Hawker

Arthritis translates to “joint inflammation.” The most common form of arthritis is osteoarthritis (OA), which affects 12-15% of North Americans over the age of 60, and will increase in prevalence as our population ages.

19 Dec 2012

Myostatin responsible for initiation of muscle loss: Study

A research study from Nanyang Technological University (NTU) has yielded important breakthroughs on how the body loses muscle, paving the way for new treatments for aging, obesity and diabetes.

19 Dec 2012

BubR1 and its associated regulators promising targets for aging disorders and cancer

A new series of studies in mouse models by Mayo Clinic researchers uncovered that the aging process is characterized by high rates of whole-chromosome losses and gains in various organs, including heart, muscle, kidney and eye, and demonstrate that reducing these rates slows age-related tissue deterioration and promotes a healthier life span. The findings appear in today's online issue of Nature Cell Biology.

18 Dec 2012

AHA/ASA identify top cardiovascular and stroke research advances for 2012

Resuscitation, cell regeneration, a new high blood pressure treatment and developments in devices for treating stroke are among the key scientific findings that make up this year's top cardiovascular and stroke research identified by the American Heart Association and American Stroke Association.

18 Dec 2012

Tbx18 gene directs conversion of cardiomyocytes to genuine pacemaker cells

Cedars-Sinai Heart Institute researchers have reprogrammed ordinary heart cells to become exact replicas of highly specialized pacemaker cells by injecting a single gene (Tbx18)-a major step forward in the decade-long search for a biological therapy to correct erratic and failing heartbeats.

18 Dec 2012

Study investigates muscle weakness in mouse model of Down syndrome

It is well known that people with Down syndrome (DS) suffer from marked muscle weakness. Even the simple tasks of independent living, such as getting out of a chair or climbing a flight of stairs, can become major obstacles. This can reduce the quality of life for those with DS and lead to a loss of independence. Now, a new study sheds light on some of the suspected causes of muscle weakness.

18 Dec 2012

GSK receives FDA approval for FLUARIX QUADRIVALENT to treat seasonal flu

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has approved FLUARIX QUADRIVALENT (Influenza Virus Vaccine) for the immunisation of children (three years and older) and adults to help prevent disease caused by seasonal influenza (flu) virus subtypes A and type B contained in the vaccine.

17 Dec 2012

Dantrolene shows promise for treating DMD

A muscle relaxant called dantrolene used for treating malignant hyperthermia boosts the activity of therapies currently being developed to treat the genetic disorder Duchenne muscular dystrophy (DMD), show study findings.

17 Dec 2012

Sit–rise test may guide mortality risk stratification

Assessing how much support a middle-aged or elderly person requires to sit and rise from the floor could be an indicator of all-cause mortality risk, researchers say.

17 Dec 2012

GTx achieves enrollment goal for pivotal Phase III clinical studies of enobosarm

GTx, Inc. today announced that it has attained its enrollment goal for both of its pivotal Phase III clinical studies of enobosarm to prevent and treat muscle wasting in non-small cell lung cancer patients.

17 Dec 2012

Aerobic training the best mode of exercise for burning fat

Aerobic training is the best mode of exercise for burning fat, according to Duke researchers who compared aerobic training, resistance training, and a combination of the two.

15 Dec 2012

Consuming whole eggs may improve blood lipids, new research suggests

It is estimated that 34% of Americans are affected by an increasingly prevalent condition known as metabolic syndrome which is a combination of at least three of the following risk factors: large waistline, high triglycerides, low HDL cholesterol, high blood pressure and elevated blood sugar.

15 Dec 2012

IOF kicks off 3rd Asia-Pacific Osteoporosis Meeting

Doctors and researchers from across the Asia-Pacific gathered today for the opening of the International Osteoporosis Foundation's (IOF) 3rd Asia-Pacific Osteoporosis Meeting, taking place at the Kuala Lumpur Convention Centre until December 16, 2012.

14 Dec 2012

Simple screening test of musculo-skeletal fitness proves predictive of all-cause mortality

A simple screening test of musculo-skeletal fitness has proved remarkably predictive of all-cause mortality in a study of more than 2000 middle-aged and older men and women.

14 Dec 2012

At-home exercise regimen sufficient to increase cancer patients' mobility and reduce fatigue

It has been known for some time that exercise is important for cancer patients, but few studies have looked at the practicality of exercise programs and whether even a minimal workout can help.

14 Dec 2012

John Wiley & Sons, TPS and APS partner to publish Physiological Reports

John Wiley & Sons, Inc., The Physiological Society (TPS), and The American Physiological Society (APS) announced today their partnership to publish the new open access peer-reviewed journal, Physiological Reports, which will launch early next year.

14 Dec 2012

Pfizer, Ligand announce FDA acceptance of bazedoxifene/conjugated estrogens NDA

Pfizer Inc. and Ligand Pharmaceuticals Incorporated today announced that the United States Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for non-hysterectomized women for the treatment of moderate-to-severe vasomotor symptoms (VMS) and vulvar and vaginal atrophy (VVA) associated with menopause, as well as the prevention of postmenopausal osteoporosis.

14 Dec 2012

Top-line results from AstraZeneca’s fostamatinib Phase IIb monotherapy study on RA

AstraZeneca today announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with selectivity for SYK (spleen tyrosine kinase) in development as an oral treatment for rheumatoid arthritis (RA).

13 Dec 2012